rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.14412/1995-4484-2010-828rsp-961Research ArticleСтатьиArticlesПоражение легких у больных ревматоидным артритом,вызванное применением базисных противовоспалительных препаратовLung lesion caused by the use of disease-modifying antirheumatic drugs in patients with rheumatoid arthritisMurav'evYuriy VladimirovichMurav'evYuriy Vladimirovichmurawyu@mail.ru <mailto:murawyu@mail.ru>МуравьевЮ. В.MuravyevYuri Vladimirovichmurawyu@mail.ru <mailto:murawyu@mail.ru>201015122010486№6 (2010)8085Copyright © Murav'ev Y.V., Муравьев Ю.В., 20102010Murav'ev Y.V., Муравьев Ю.В.Murav'ev Y.V., Muravyev Y.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/961References<div><p>Wolfe F., Mitchell D.M., Sibley J.T. et al. The mortality of rheumatoid arthritis. Arthr Rheum 1994; 37: 481-94.</p><p>Tomioka H., King T.E. Gold-induced pulmonary disease: clinical features, outcome, and differentiation from rheumatoid lung disease. Am J Respir Crit Care Med 1997; 155: 1011-20.</p><p>Kay A. European League Against Rheumatism study of adverse reactions to D- penicillamine. Br J Rheumatol 1986; 25: 193-8.</p><p>Ulubas B., Sahin G., Ozer C. et al. Bronchiolitis obliterans organizing pneumonia associated with sulfasalazine in a patient with rheumatoid arthritis. Clin Rheumatol 2004; 23: 249-51.</p><p>Hamadeh M.A., Atkinson J., Smith L.J. Sulfasalazine-induced pulmonary disease. Chest 1992; 101: 1033-7.</p><p>Cannon G.W., Ward J.R., Clegg D.O. et al. Acute lung disease associated with low- dose pulse methotrexate therapy in patients with rheumatoid arthritis. Arthr Rheum 1983; 26: 1269-74.</p><p>Engelbrecht J.A., Calhoon S.L., Scherrer J.J. Methotrexate pneumonitis after low-dose therapy for rheumatoid arthritis. Arthr Rheum 1983; 26: 1275-8.</p><p>Barrera P., Laan R.F., van Riel P.L. et al. Methotrexate related pulmonary complications in rheumatoid arthritis. Ann Rheum Dis 1994; 53: 434-9.</p><p>Alarcon G.S., Kremer J.M., Macaluso M. et al. Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis. A multicenter, case-control study. Methotrexate-Lung Study Group. Ann Intern Med 1997; 127: 356-64.</p><p>Golden M.R., Katz R.S., Balk R.A., Golden H.E. The relationship of preexisting lung disease to the development of methotrexate pneumonitis in patients with rheumatoid arthritis. J Rheumatol 1995; 22: 1043-7.</p><p>Ohosone Y., Okano Y., Kameda H. et al. Clinical characteristics of patients with rheumatoid arthritis and methotrexate induced pneumonitis. J Rheumatol 1997; 24: 2299-303.</p><p>Федеральное руководство по использованию лекарственных средств (формулярная система). Вып. XI. М.: Эхо, 2010; 944 с.</p><p>Ревматология: Клинические рекомендации. Под ред. акад. РАМН Е.Л. Насонова. 2-е изд., испр. и доп. М.: ГЭОТАР-Медиа, 2010; 752 с.</p><p>Engelbrecht J.A., Calhon S.L., Shcerer J.J. et al. Methotrexate pneumonitis after low-dose therapy for rheumatoid arthritis. Arthr Rheum 1983; 26: 1275-9.</p><p>Louie S., Lilington G.A. Low dosemethotrexate pneumonitis in rheumatoid arthritis. Thorax 1986; 41: 703-4.</p><p>Searles G., McKendry J.R. Methotrexate pneumonitis in rheumatoid arthritis: potential rick factors. Four case reports and review of the literature. J Rheumatol 1987; 14: 1164-70.</p><p>Carson B.C.W., Cannon G.W., Egger M.J. et al. Pulmonary disease during the treatment of rheumatoid arthritis with low dose pulse methotrexat. Semin Arthr Rheum 1987; 16: 188-95.</p><p>Roenigk H.H., Auerbach R., Maibach H.I., Weinstein G.D. Methotrexate guidelines - revised. J Am Acad Dermatol 1982; 6: 145-55.</p><p>Ridley M.G., Wolfe C.S., Mathews J.A. Life threatening acute pneumonitis during low dose methotrexate treatment for rheumatoid arthritis: a case report and review of the literature. Ann Rheum Dis 1988; 47: 784-8.</p><p>Panay G.S., Wooley P., Batcheler J.R. Genetic basis of rheumatoid disease: HLA antigens, disease manifestations and toxic reactions to drugs. Br Med J 1978; 2: 1326-8.</p><p>Kim Y.J., Song M., Ryu J.C. Inflammation in methotrexate-induced pulmonary toxicity occurs via the p38 MAPK pathway. Toxicology 2009; 256: 183-90.</p><p>Stenger A.A., Houtman P.M., Bruyn G.A. et al. Pneucystis carnii pneumonia associated with low dose methotrexate treatment for rheumatoid arthritis. Scand J Rheumatol 1994; 23: 51-3.</p><p>Ohosone Y., Okano Y., Kameda H. et al. Clinical characteristics of patients with rheumatoid arthritis and methotrexate induced pneumonitis. J Rheumatol 1997; 24: 2299-303.</p><p>Wollner A., Mohle-Boetani J., Lambert R.E. Pneumocystis carnii pneumonia complicating low dose methotrexate treatment for rheumatoid arthritis. Thorax 1991; 46: 205-7.</p><p>Frank S.T., Weg J.G., Harkleorad L.E., Fitch R.F. Pulmonary dysfunction in rheumatoid disease. Chest 1973; 63: 27-33.</p><p>Kremer J.M., Alarcon G.S., Weinblatt M.E. et al. Clinical, laboratory, radiographic, and histopathologic features of methotrexate associated lung injury in patients with rheumatoid arthritis. Arthr Rheum 1997; 40: 1829-37.</p><p>Schnabel A., Richter C., Bauerfeind S., Gross W.L. Bronchoalveolar lavage cell profile in methotrexate induced pneumonitis. Thorax 1997; 52: 377-9.</p><p>Wolfe F., Caplan L., Michaeud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia. Arthr Rheum 2006; 54: 628-34.</p><p>Чучалин А.Г., Синопальников А.И., Страчунский Л.С. и др. Внебольничная пневмония у взрослых: практические рекомендации по диагностике, лечению и профилактике. М.: ООО «Издательский дом «М-Вести», 2006; 76 с.</p><p>Kalden J.R., Schattenkirchner M., Sorensen H. et al. The efficacy and safety of leflunomide in patients with active rheumatoid arthritis: a five year follow up study. Arthr Rheum 2003; 48: 1513-20.</p><p>Ito S., Sumida T. Interstitial lung disease associated with leflunomide. Intern Med 2004; 43: 1103-4.</p><p>McCurry J. Japan deaths spark concerns over arthritis drug. Lancet 2004; 363: 461.</p><p>Takeishi M., Akiyama Y., Akiba H. et al. Leflunomide induced acute interstitial pneumonia. J Rheumatol 2005; 32: 1160-3.</p><p>Suissa S., Hudson M., Ernst P. Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis. Arthr Rheum 2006; 54: 1435-9.</p><p>Sawada T., Inokuma S., Sato T. et al. Leflunomide induced interstitial lung disease; prevalence and risk factors in Japanese patients with rheumatoid arthritis. Rheumatology 2009; 48: 1069-72.</p><p>Savage R.L., Highton J., Boyd I.W., Chapman P. Pneumonitis associated with leflunomide: a profile of New Zealand and Australian reports. Intern Med J 2006; 36: 162-9.</p><p>Kelly C. Leflunomide and the lung. Rheumatology 2009; 48: 1017-8.</p><p>Chikura B., Lane S., Dawson J. Clinical expression of leflunomide induced pneumonitis. Rheumatology 2009; 48: 1065-8.</p><p>Peno-Green L., Lluberas G., Kingsley T. et al. Lung injury linked to etanercept therapy. Chest 2002; 122: 1858-60.</p><p>Roos J.C., Chilvers E.R., Ostor A.J. Interstitial pneumonitis and anti-tumor necrosis factor-α therapy. J Rheumatol 2007; 34: 238-9.</p><p>Gosset P., Perez T., Lassalle P. et al. Increased TNF-α secretion by alveolar macrophages from patients with rheumatoid arthritis. Am Rev Respir Dis 1991; 143: 593-7.</p><p>Elias J.A. Tumor necrosis factor interacts with interleukin 1 and interferons to inhibit fibroblast proliferation via fibroblast prostaglandin dependent and independent mechanisms. Am Rev Respir Dis 1988; 13: 652-8.</p><p>Ancochea J., Giron R.M., Lopez-Botet M. Production of tumor necrosis factor alpha and interleukin-6 by alveolar macrophages from patients with rheumatoid arthritis and interstitial pulmonary disease. Arch Bronconeumol 1997; 33: 335-40.</p><p>Turesson C., Matteson E.L., Colby T.V. Increased CD4+ T cell infiltrates in rheumatoid arthritis-associated interstitial pneumonitis compared with idiopathic interstitial pneumonitis. Arthr Rheum 2005; 52: 73-9.</p><p>Nagasava Y., Takada T., Shimizu T. et al. Inflammatory cell in lung disease associated with rheumatoid arthritis. Intern Med 2009; 48: 1209-17.</p><p>Burton C., Kaczmarski R., Jan-Mohamed R. Interstitial pneumonitis related to rituximab therapy. N Engl J Med 2003; 348: 2690-1.</p><p>Leon R.J., Gonsalvo A., Salas R., Hidalgo N.C. Rituximab-induced acute pulmonary fibrosis. Mayo Clin Proc 2004; 79: 949-53.</p><p>Saito B., Nakamaki T., Adachi D. et al. Acute respiratory distress syndrome during the third infusion of rituximab in a patient with follicular lymphoma. Int J Hematol 2004; 80: 164-7.</p><p>Jullien V., Perrin C., Peyrade F. et al. Alveolar hypoxemic interstitial pneumonia related to rituximab therapy. Rev Mal Respir 2004; 21: 407-10.</p><p>Wagner S.A., Mehta A.C., Laber D.A. Rituximab-induced interstitial lung disease. Am J Hematol 2007; 82: 916-9.</p><p>Bienvenu J., Chvetzoff R., Salles G. et al. Tumor necrosis factor a release is a major biological event associated with rituximab therapy. Hematol J 2001; 2: 378-84.</p><p>Hiraga J., Kondoh Y., Taniguchi H. et al. A case of interstitial pneumonia induced by rituximab therapy. Int J Hematol 2005; 81: 169-70.</p><p>Alho H.S., Maasitta P.K., Harjula A.L. et al. Tumor necrosis factor-a in a porcine bronchial model of obliterative bronchiolitis. Transplantation 2003; 76: 516-23.</p><p>Heresi G.A., Farver C.F., Stoller J.K. Interstitial pneumonitis and alveolar hemorrhage complicating use of rituximab: case report and review of the literature. Respiration 2008; 76: 449-53.</p><p>Genentech: Rituxan: highlights of prescribing information, revised January 2008. http://www.gene.com/gene/products/infor mation/pdf/rituxan-prescribing.pdf</p><p>Tonelli A.R., Lottenberg R., Allan R.W., Sriram P.S. Rituximab-induced hypersensitivity pneumonitis. Respiration 2009; 78: 225-9.</p><p>Chaumais M.C., Garnier A., Chalard F. et al. Fatal pulmonary fibrosis after rituximab administration. Pediatr Nephrol 2009; 24: 1753-5.</p><p>Liote H., Liote F., Seroussi B. et al. Rituximab-induced lung disease: a systematic literature review. Eur Respir J 2009, Jul 16 [Epub. ahead of print].</p><p>Bouldouyre M.A., Cohen P., Guillevin L. Severe bronchospasm associated with rituximab for refractory Churg-Strauss syndrome. Ann Rheum Dis 2009; 68: 606.</p><p>Fujiwara H., Nishimoto N., Hamano Y. et al. Masked early symptoms of pneumonia in patients with rheumatoid arthritis during tocilizumab treatment: a report of two cases. Mod Rheumatol 2009; 19: 64-8.</p><p>Veerappan S.G., O'Morain C.A. Infliximab-associated alveolitis after treatment for severe left-sided ulcerative colitis. Eur J Gastroenterol Hepatol 2009; 21: 830-2.</p><p>Dascalu C., Mrejen-Shakin K., Bandagi S. Adalimumab-induced acute pneumonitis in a patient with rheumatoid arthritis. J Clin Rheumatol 2010; 16: 172-4.</p><p>Bruce J. Rule out ILD in RA patients' Lung problem. Rheumatology News 2010; 9: 19.</p></div><br /><div><p>Wolfe F., Mitchell D.M., Sibley J.T. et al. The mortality of rheumatoid arthritis. Arthr Rheum 1994; 37: 481-94.</p><p>Tomioka H., King T.E. Gold-induced pulmonary disease: clinical features, outcome, and differentiation from rheumatoid lung disease. Am J Respir Crit Care Med 1997; 155: 1011-20.</p><p>Kay A. European League Against Rheumatism study of adverse reactions to D- penicillamine. Br J Rheumatol 1986; 25: 193-8.</p><p>Ulubas B., Sahin G., Ozer C. et al. Bronchiolitis obliterans organizing pneumonia associated with sulfasalazine in a patient with rheumatoid arthritis. Clin Rheumatol 2004; 23: 249-51.</p><p>Hamadeh M.A., Atkinson J., Smith L.J. Sulfasalazine-induced pulmonary disease. Chest 1992; 101: 1033-7.</p><p>Cannon G.W., Ward J.R., Clegg D.O. et al. Acute lung disease associated with low- dose pulse methotrexate therapy in patients with rheumatoid arthritis. Arthr Rheum 1983; 26: 1269-74.</p><p>Engelbrecht J.A., Calhoon S.L., Scherrer J.J. Methotrexate pneumonitis after low-dose therapy for rheumatoid arthritis. Arthr Rheum 1983; 26: 1275-8.</p><p>Barrera P., Laan R.F., van Riel P.L. et al. Methotrexate related pulmonary complications in rheumatoid arthritis. Ann Rheum Dis 1994; 53: 434-9.</p><p>Alarcon G.S., Kremer J.M., Macaluso M. et al. Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis. A multicenter, case-control study. Methotrexate-Lung Study Group. Ann Intern Med 1997; 127: 356-64.</p><p>Golden M.R., Katz R.S., Balk R.A., Golden H.E. The relationship of preexisting lung disease to the development of methotrexate pneumonitis in patients with rheumatoid arthritis. J Rheumatol 1995; 22: 1043-7.</p><p>Ohosone Y., Okano Y., Kameda H. et al. Clinical characteristics of patients with rheumatoid arthritis and methotrexate induced pneumonitis. J Rheumatol 1997; 24: 2299-303.</p><p>Федеральное руководство по использованию лекарственных средств (формулярная система). Вып. XI. М.: Эхо, 2010; 944 с.</p><p>Ревматология: Клинические рекомендации. Под ред. акад. РАМН Е.Л. Насонова. 2-е изд., испр. и доп. М.: ГЭОТАР-Медиа, 2010; 752 с.</p><p>Engelbrecht J.A., Calhon S.L., Shcerer J.J. et al. Methotrexate pneumonitis after low-dose therapy for rheumatoid arthritis. Arthr Rheum 1983; 26: 1275-9.</p><p>Louie S., Lilington G.A. Low dosemethotrexate pneumonitis in rheumatoid arthritis. Thorax 1986; 41: 703-4.</p><p>Searles G., McKendry J.R. Methotrexate pneumonitis in rheumatoid arthritis: potential rick factors. Four case reports and review of the literature. J Rheumatol 1987; 14: 1164-70.</p><p>Carson B.C.W., Cannon G.W., Egger M.J. et al. Pulmonary disease during the treatment of rheumatoid arthritis with low dose pulse methotrexat. Semin Arthr Rheum 1987; 16: 188-95.</p><p>Roenigk H.H., Auerbach R., Maibach H.I., Weinstein G.D. Methotrexate guidelines - revised. J Am Acad Dermatol 1982; 6: 145-55.</p><p>Ridley M.G., Wolfe C.S., Mathews J.A. Life threatening acute pneumonitis during low dose methotrexate treatment for rheumatoid arthritis: a case report and review of the literature. Ann Rheum Dis 1988; 47: 784-8.</p><p>Panay G.S., Wooley P., Batcheler J.R. Genetic basis of rheumatoid disease: HLA antigens, disease manifestations and toxic reactions to drugs. Br Med J 1978; 2: 1326-8.</p><p>Kim Y.J., Song M., Ryu J.C. Inflammation in methotrexate-induced pulmonary toxicity occurs via the p38 MAPK pathway. Toxicology 2009; 256: 183-90.</p><p>Stenger A.A., Houtman P.M., Bruyn G.A. et al. Pneucystis carnii pneumonia associated with low dose methotrexate treatment for rheumatoid arthritis. Scand J Rheumatol 1994; 23: 51-3.</p><p>Ohosone Y., Okano Y., Kameda H. et al. Clinical characteristics of patients with rheumatoid arthritis and methotrexate induced pneumonitis. J Rheumatol 1997; 24: 2299-303.</p><p>Wollner A., Mohle-Boetani J., Lambert R.E. Pneumocystis carnii pneumonia complicating low dose methotrexate treatment for rheumatoid arthritis. Thorax 1991; 46: 205-7.</p><p>Frank S.T., Weg J.G., Harkleorad L.E., Fitch R.F. Pulmonary dysfunction in rheumatoid disease. Chest 1973; 63: 27-33.</p><p>Kremer J.M., Alarcon G.S., Weinblatt M.E. et al. Clinical, laboratory, radiographic, and histopathologic features of methotrexate associated lung injury in patients with rheumatoid arthritis. Arthr Rheum 1997; 40: 1829-37.</p><p>Schnabel A., Richter C., Bauerfeind S., Gross W.L. Bronchoalveolar lavage cell profile in methotrexate induced pneumonitis. Thorax 1997; 52: 377-9.</p><p>Wolfe F., Caplan L., Michaeud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia. Arthr Rheum 2006; 54: 628-34.</p><p>Чучалин А.Г., Синопальников А.И., Страчунский Л.С. и др. Внебольничная пневмония у взрослых: практические рекомендации по диагностике, лечению и профилактике. М.: ООО «Издательский дом «М-Вести», 2006; 76 с.</p><p>Kalden J.R., Schattenkirchner M., Sorensen H. et al. The efficacy and safety of leflunomide in patients with active rheumatoid arthritis: a five year follow up study. Arthr Rheum 2003; 48: 1513-20.</p><p>Ito S., Sumida T. Interstitial lung disease associated with leflunomide. Intern Med 2004; 43: 1103-4.</p><p>McCurry J. Japan deaths spark concerns over arthritis drug. Lancet 2004; 363: 461.</p><p>Takeishi M., Akiyama Y., Akiba H. et al. Leflunomide induced acute interstitial pneumonia. J Rheumatol 2005; 32: 1160-3.</p><p>Suissa S., Hudson M., Ernst P. Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis. Arthr Rheum 2006; 54: 1435-9.</p><p>Sawada T., Inokuma S., Sato T. et al. Leflunomide induced interstitial lung disease; prevalence and risk factors in Japanese patients with rheumatoid arthritis. Rheumatology 2009; 48: 1069-72.</p><p>Savage R.L., Highton J., Boyd I.W., Chapman P. Pneumonitis associated with leflunomide: a profile of New Zealand and Australian reports. Intern Med J 2006; 36: 162-9.</p><p>Kelly C. Leflunomide and the lung. Rheumatology 2009; 48: 1017-8.</p><p>Chikura B., Lane S., Dawson J. Clinical expression of leflunomide induced pneumonitis. Rheumatology 2009; 48: 1065-8.</p><p>Peno-Green L., Lluberas G., Kingsley T. et al. Lung injury linked to etanercept therapy. Chest 2002; 122: 1858-60.</p><p>Roos J.C., Chilvers E.R., Ostor A.J. Interstitial pneumonitis and anti-tumor necrosis factor-α therapy. J Rheumatol 2007; 34: 238-9.</p><p>Gosset P., Perez T., Lassalle P. et al. Increased TNF-α secretion by alveolar macrophages from patients with rheumatoid arthritis. Am Rev Respir Dis 1991; 143: 593-7.</p><p>Elias J.A. Tumor necrosis factor interacts with interleukin 1 and interferons to inhibit fibroblast proliferation via fibroblast prostaglandin dependent and independent mechanisms. Am Rev Respir Dis 1988; 13: 652-8.</p><p>Ancochea J., Giron R.M., Lopez-Botet M. Production of tumor necrosis factor alpha and interleukin-6 by alveolar macrophages from patients with rheumatoid arthritis and interstitial pulmonary disease. Arch Bronconeumol 1997; 33: 335-40.</p><p>Turesson C., Matteson E.L., Colby T.V. Increased CD4+ T cell infiltrates in rheumatoid arthritis-associated interstitial pneumonitis compared with idiopathic interstitial pneumonitis. Arthr Rheum 2005; 52: 73-9.</p><p>Nagasava Y., Takada T., Shimizu T. et al. Inflammatory cell in lung disease associated with rheumatoid arthritis. Intern Med 2009; 48: 1209-17.</p><p>Burton C., Kaczmarski R., Jan-Mohamed R. Interstitial pneumonitis related to rituximab therapy. N Engl J Med 2003; 348: 2690-1.</p><p>Leon R.J., Gonsalvo A., Salas R., Hidalgo N.C. Rituximab-induced acute pulmonary fibrosis. Mayo Clin Proc 2004; 79: 949-53.</p><p>Saito B., Nakamaki T., Adachi D. et al. Acute respiratory distress syndrome during the third infusion of rituximab in a patient with follicular lymphoma. Int J Hematol 2004; 80: 164-7.</p><p>Jullien V., Perrin C., Peyrade F. et al. Alveolar hypoxemic interstitial pneumonia related to rituximab therapy. Rev Mal Respir 2004; 21: 407-10.</p><p>Wagner S.A., Mehta A.C., Laber D.A. Rituximab-induced interstitial lung disease. Am J Hematol 2007; 82: 916-9.</p><p>Bienvenu J., Chvetzoff R., Salles G. et al. Tumor necrosis factor a release is a major biological event associated with rituximab therapy. Hematol J 2001; 2: 378-84.</p><p>Hiraga J., Kondoh Y., Taniguchi H. et al. A case of interstitial pneumonia induced by rituximab therapy. Int J Hematol 2005; 81: 169-70.</p><p>Alho H.S., Maasitta P.K., Harjula A.L. et al. Tumor necrosis factor-a in a porcine bronchial model of obliterative bronchiolitis. Transplantation 2003; 76: 516-23.</p><p>Heresi G.A., Farver C.F., Stoller J.K. Interstitial pneumonitis and alveolar hemorrhage complicating use of rituximab: case report and review of the literature. Respiration 2008; 76: 449-53.</p><p>Genentech: Rituxan: highlights of prescribing information, revised January 2008. http://www.gene.com/gene/products/infor mation/pdf/rituxan-prescribing.pdf</p><p>Tonelli A.R., Lottenberg R., Allan R.W., Sriram P.S. Rituximab-induced hypersensitivity pneumonitis. Respiration 2009; 78: 225-9.</p><p>Chaumais M.C., Garnier A., Chalard F. et al. Fatal pulmonary fibrosis after rituximab administration. Pediatr Nephrol 2009; 24: 1753-5.</p><p>Liote H., Liote F., Seroussi B. et al. Rituximab-induced lung disease: a systematic literature review. Eur Respir J 2009, Jul 16 [Epub. ahead of print].</p><p>Bouldouyre M.A., Cohen P., Guillevin L. Severe bronchospasm associated with rituximab for refractory Churg-Strauss syndrome. Ann Rheum Dis 2009; 68: 606.</p><p>Fujiwara H., Nishimoto N., Hamano Y. et al. Masked early symptoms of pneumonia in patients with rheumatoid arthritis during tocilizumab treatment: a report of two cases. Mod Rheumatol 2009; 19: 64-8.</p><p>Veerappan S.G., O'Morain C.A. Infliximab-associated alveolitis after treatment for severe left-sided ulcerative colitis. Eur J Gastroenterol Hepatol 2009; 21: 830-2.</p><p>Dascalu C., Mrejen-Shakin K., Bandagi S. Adalimumab-induced acute pneumonitis in a patient with rheumatoid arthritis. J Clin Rheumatol 2010; 16: 172-4.</p><p>Bruce J. Rule out ILD in RA patients' Lung problem. Rheumatology News 2010; 9: 19.</p></div><br />
The authors declare that there are no conflicts of interest present.